Medizinische Universität Graz - Research portal
Selected Publication:
Becker, JC; Varki, N; Gillies, SD; Furukawa, K; Reisfeld, RA.
Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy
J CLIN INVEST. 1996; 98(12): 2801-2804.
Doi: 10.1172/JCI119107
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- A major goal of tumor immunotherapy is the induction of tumor-specific T cell responses that are effective in eradicating disseminated tumor, as well as mounting a persistent tumor-protective immunity. We demonstrate here that a genetically engineered fusion protein consisting of human/mouse chimeric anti-ganglioside GD(2) antibody and human interleukin-2 is able to induce eradication of established B78-D14 melanoma metastases in immunocompetent syngeneic C57BL/6J mice. This therapeutic effect is mediated by host immune cells, particularly CD8(+) T cells and is associated with the induction of a long-lived immunity preventing tumor growth in the majority of animals when challenged up to four months later with B78-D14 cells. This effect was tumor-specific, since no cross-protection against syngeneic, ganglioside GD(2)+EL-4 thymoma cells was observed. Furthermore, this tumor-specific protection can be transmitted horizontally to naive, syngeneic SCID mice by passive transfer of CD8(+) T lymphocytes derived from immune animals. These results suggest that antibody-targeted delivery of cytokines provides a means to elicit effective immune responses against established tumors in the immunotherapy of neoplastic disease.
- Find related publications in this database (Keywords)
- antibody
- cytokine
- fusion protein
- melanoma
- T cell